Temporal changes of soluble ST2 after cardiovascular interventions
- 31 October 2012
- journal article
- research article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 43 (2) , 113-120
Abstract
Background Soluble ST2 (sST2), a member of the IL-1 receptor family, has been proposed as a novel biomarker with predictive value for heart failure and mortality in patients suffering from cardiovascular diseases. The influence of clinical characteristics on variability of sST2 levels is relatively unexplored. Here, we studied the effect of cardiovascular interventions and clinical characteristics on plasma sST2 expression levels. Material and methods In the current study, sST2 levels were assessed in the plasma of patients scheduled for coronary artery bypass grafting (CABG) (n = 76), percutaneous coronary intervention (PCI) (n = 68) or peripheral vascular surgery (n = 27). Results Age was the only classical risk factor significantly correlating with sST2 levels. Soluble ST2 levels were significantly increased 1 h after CABG (48 [33–70] vs. 61 [42–89] pg/mL, P = 0·001) and increased even further after 24 h (1116 [578–13 666] pg/mL, P < 0·001). An average threefold increase in sST2 levels was also observed in patients 24 h after peripheral interventions (30 [21–41] vs. 98 [48–211] pg/mL, P < 0·001). Two months after PCI, we found that sST2 levels were significantly higher compared with baseline levels (41 [29–61] vs. 48 [31–80] pg/mL, P = 0·007, n = 52). In addition, we did not observe an association between sST2 and any inflammatory or cardiac-specific markers that were measured in this study. Conclusions Soluble ST2 increases significantly following cardiovascular interventions. The notion of a recent cardiovascular intervention is a strong determinant of sST2 levels and therefore needs to be taken into account when exploring sST2 as predictor of future cardiovascular events.Keywords
This publication has 38 references indexed in Scilit:
- IL-33 Expands Suppressive CD11b+ Gr-1int and Regulatory T Cells, including ST2L+ Foxp3+ Cells, and Mediates Regulatory T Cell-Dependent Promotion of Cardiac Allograft SurvivalThe Journal of Immunology, 2011
- Interleukin 33 and ST2 in non–ST-elevation myocardial infarction: Comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNPAmerican Heart Journal, 2011
- High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart FailureCirculation: Heart Failure, 2011
- Adenovirus-mediated overexpression of soluble ST2 provides a protective effect on lipopolysaccharide-induced acute lung injury in miceClinical and Experimental Immunology, 2011
- Measurement of Interleukin-33 (IL-33) and IL-33 Receptors (sST2 and ST2L) in Patients with Rheumatoid ArthritisJournal of Korean Medical Science, 2011
- Soluble ST2 Levels Are Associated with Bleeding in Patients with Severe LeptospirosisPLOS Neglected Tropical Diseases, 2009
- Nonmyocardial Production of ST2 Protein in Human Hypertrophy and Failure Is Related to Diastolic LoadJACC, 2008
- IL-33 reduces the development of atherosclerosisJournal of Experimental Medicine, 2008
- IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling systemJournal of Clinical Investigation, 2007
- ST2 suppresses IL-6 production via the inhibition of IκB degradation induced by the LPS signal in THP-1 cellsBiochemical and Biophysical Research Communications, 2006